1. Show article details.

    BRIEF-Keros Therapeutics Reports Recent Business Highlights And Second Quarter 2022 Financial Results

    Reuters – 4:53 PM ET 08/04/2022

    Keros Therapeutics Inc (KROS): * KEROS THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2022 FINANCIAL RESULTS. * Keros Therapeutics Inc (KROS) - STRENGTHENED CASH POSITION AND EXTENDED CASH RUNWAY TO FUND OPERATIONS INTO Q3 2024. * Keros Therapeutics Inc (KROS) - QTRLY LOSS PER SHARE $1.13 Source text for Eikon: Further company coverage:

  2. Show article details.

    Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

    GlobeNewswire – 4:01 PM ET 08/04/2022

    KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patients; 44% of high transfusion burden patients achieved transfusion independence KER-012 preliminary Phase 1 data exhibited encouraging treatment profile in healthy volunteers with improvements in biomarkers of bone f...

  3. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022

    Benzinga – 10:30 AM ET 07/26/2022

    For Agile Therapeutics Inc, Maxim Group upgraded the previous rating of Hold to Buy. According to JP Morgan, the prior rating for Zymergen Inc was changed from Underweight to Neutral. See all analyst ratings upgrades. For Revolve Group Inc, B of A Securities downgraded the previous rating of Buy to Underperform.

  4. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 12:32 PM ET 06/23/2022

      On Thursday, 216 stocks hit new 52-week lows. Stocks that set new 52-week lows on Thursday are as follows: Be sure to monitor Benzinga for the news traders need!

  5. Show article details.

    Stocks That Hit 52-Week Lows On Tuesday

    Benzinga – 12:11 PM ET 06/14/2022

      On Tuesday, 951 companies hit new 52-week lows. On Tuesday, the following stocks set new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  6. Show article details.

    BRIEF-Keros Therapeutics Presents Results From Preclinical Study Of Rker-012 In Pulmonary Arterial Hypertension At Pulmonary Hypertension Association International Conference And Scientific Sessions

    Reuters – 8:28 AM ET 06/13/2022

    Keros Therapeutics Inc (KROS): * KEROS THERAPEUTICS PRESENTS RESULTS FROM A PRECLINICAL STUDY OF RKER-012 IN PULMONARY ARTERIAL HYPERTENSION AT PULMONARY HYPERTENSION ASSOCIATION INTERNATIONAL CONFERENCE AND SCIENTIFIC SESSIONS Source text for Eikon: Further company coverage:

  7. Show article details.

    Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

    GlobeNewswire – 8:00 AM ET 06/13/2022

    Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical study of RKER-012 on cardiac and pulmonary pathology in an established rodent model of pulmonary arteri...

  8. Show article details.

    Stocks That Hit 52-Week Lows On Friday

    Benzinga – 11:45 AM ET 06/10/2022

      On Friday, 422 stocks made new 52-week lows. These stocks set new 52-week lows on Friday: Be sure to monitor Benzinga for the news traders need!

  9. Show article details.

    Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

    GlobeNewswire – 6:00 AM ET 06/10/2022

    Keros Therapeutics (KROS), Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermed...

  10. Show article details.

    76 Biggest Movers From Yesterday

    Benzinga – 4:45 AM ET 05/19/2022

       

  11. Show article details.

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    Benzinga – 2:08 PM ET 05/18/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  12. Show article details.

    Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial

    Benzinga – 12:38 PM ET 05/18/2022

    Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial

  13. Show article details.

    Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure

    Benzinga – 12:25 PM ET 05/18/2022

    Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure

  14. Show article details.

    The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact

    Benzinga – 10:15 AM ET 05/18/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. The FDA has authorized a booster shot of Pfizer Inc  and BioNTech SE's  COVID-19 vaccine for children aged 5 to 11. The move makes everyone in the U.S over the age of 5 eligible for a third shot or a booster. Aquestive Therapeutics Inc  CEO, president and board member, Keith Kendall, is leaving the company.

  15. Show article details.

    BRIEF-Keros Therapeutics Announces Preliminary Topline Results From Its Ongoing Phase 1 Clinical Trial Evaluating KER-012 In Healthy Volunteers

    Reuters – 6:05 AM ET 05/18/2022

    Keros Therapeutics Inc (KROS): * KEROS THERAPEUTICS ANNOUNCES PRELIMINARY TOPLINE RESULTS FROM ITS ONGOING PHASE 1 CLINICAL TRIAL EVALUATING KER-012 IN HEALTHY VOLUNTEERS. * Keros Therapeutics Inc (KROS) - KER-012 WAS GENERALLY WELL TOLERATED IN PART 1 OF TRIAL. * Keros Therapeutics Inc (KROS) - ONE SUBJECT WITHDREW CONSENT AFTER RECEIVING A SINGLE 1.5 MG/KG DOSE OF KER-012.

  16. Show article details.

    Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

    GlobeNewswire – 6:00 AM ET 05/18/2022

    Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced preliminary topline results from Part 1 of its Phase 1 clinical trial evaluating single and multiple ascending doses of KER-012 in...

  17. Show article details.

    BRIEF-Keros Therapeutics Presents Results From A Preclinical Study Of RKER-012 In Pulmonary Arterial Hypertension

    Reuters – 4:50 PM ET 05/17/2022

    Keros Therapeutics Inc (KROS): * KEROS THERAPEUTICS PRESENTS RESULTS FROM A PRECLINICAL STUDY OF RKER-012 IN PULMONARY ARTERIAL HYPERTENSION AT THE AMERICAN THORACIC SOCIETY INTERNATIONAL CONFERENCE Source text for Eikon: Further company coverage:

  18. Show article details.

    Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

    GlobeNewswire – 4:01 PM ET 05/17/2022

    Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical study of RKER-012 on pulmonary arterial pressure and right ventricle hypertrophy in an established rode...

  19. Show article details.

    Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

    GlobeNewswire – 4:01 PM ET 05/12/2022

    Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need today announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 27th Annual Congress of the European He...

  20. Show article details.

    Keros Therapeutics: Q1 Earnings Insights

    Benzinga – 9:02 AM ET 05/05/2022

      Keros Therapeutics reported its Q1 earnings results on Thursday, May 5, 2022. Here's what investors need to know about the announcement. Keros Therapeutics missed estimated earnings by 17.44%, reporting an EPS of $-1.01 versus an estimate of $-0.86. Revenue was down $0.00 from the same period last year.

Page:

Today's and Upcoming Events

  • Nov
    02

    KROS to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    04

    KROS announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.